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N. Ernst, M-J. de Boer, F. Zijlstr, H. Suryapranata, J-H.E. Dambrink, J.C.A Hoornje, A.W.J. van 't Hof,
on behalf ofthe Zwolle Myocardial Infarction Study Group
Primary coronary angioplasty has been shown to
be an effective reperfusion therapy for patients with
acute myocardial infarction, not only for thosewho
present to PTCA centres but also for patients who
present to hospitals without angioplasty facilities.
With the increasing use of primary angioplasty
more patients will be transferred to a (tertiary)
PTCA centre. An increase in treatment delay is
associated with a worse clinical outcome. The
importance ofan open infarct-related vessel at acute
angiography is becoming dear. Pharmacological
pretreatment ofpatients during transportation to
a PTCA centre with the aim to open the infarct-
related vessel in advance might be beneficial.
Glycoprotein llb/Ma receptoi- blockers seem to
be the agents of choice for facilitated PTCK The
safety and (cost) effectiveness ofthis pretreatment
ofpatients transported to undergo primary angio-
plasty remain to be evaluated. (Netb Heart J
2006;14:55-61.)
Keywords: PTCA, ransportation, myocardial infarction
Drmary coronary angioplasty in patients with acute
Vmyocardial infarction (MI) has been shown to be
an effective reperfusion therapy both at short- and
long-term follow-up. In 1993 the first randomised
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thrombolytic therapy in acute myocardial infarction
reported a better clinical outcome with immediate
coronary angioplasty." 2 This was also confirmed at
long-term follow-up.3 The use of stents may further
improve outcome after primary angioplasty.4'5 These
studies were all performed in centres with PTCA
facilities. However, even when transfer to an angio-
plasty centre is necessary, primary angioplasty remains
superior to immediate thrombolytic therapy.6 Results
can be further improved by pharmacological pre-
treatment during transportation with the aim to
improve patency of the infarct-related vessel before
primary angioplasty.
Effect of treatment delay on outcome
Recent European (2003) and American guidelines
(2004) for treatment ofacute MI report that patients
in cardiogenic shock and patients with contraindications
for thrombolytic therapy have a class I indication for
transportation to a PTCA centre to undergo primary
angioplasty.7'8 In addition, primary angioplasty is the
treatment of choice in high-risk patients (large MI,
Killip class III) whenever the procedure can be per-
formed within 90 minutes after diagnosis. Trans-
portation ofpatients with acute MI is safe and feasible
but may lead to an increase in treatment delay. Zijlstra
et al. reported in 1997 that the influence of trans-
portation on total ischaemic time was limited and that
there was no difference in clinical outcome at six
months between the transferred (high-risk) patients
and the nontransferred patients.9 However, an increase
in treatment delay of 45 minutes in patients in the
early phase of acute anterior myocardial infarction is
associated with a larger infarct size and a worse left
ventricular ejection fraction.10 De Luca et al. showed
that every minute of delay counts, so that all efforts
should be made to shorten the total ischaemic time
for patients treated with primary angioplasty." Also
data from the NRMI-2 registry ofmore than 27,000
patients from 661 hospitals in the United States
elegantly showed the relationship between increased
mortality and delay in door-to-balloon time, especially
when door-to-balloon time is greater than 120
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Figure 1. Door-to-balloon time vs. mortality (multivariate adjusted
odds). Reprinted withpermissionfrom the author.12
minutes (figure 1 ).12 Door-to-balloon time was more
than two hours in nearly 50% ofpatients in this cohort.
Reduction of treatment delay using prehospital
Infarct diagnosis and trlage
It is possible to achieve a further reduction in time to
treatment by infarct diagnosis and risk stratification in
the ambulance. The PHIAT (PreHospital Infarction
Angioplasty Triage) registry performed in the Zwolle
region included more than 200 patients in two years
time.'3 When patients were identified as having a large
acute MI (i.e. fulfilling electrocardiographic criteria
with respect to cumulative ST-segment deviation),
immediate transfer to a PTCA centre and preparation
of cath lab and personnel were initiated. This was
associated with a reduction in total ischaemic time of
45 to 60 minutes compared with patients seen
primarily in the emergency room or referred from one
ofthe surrounding non-PTCA centres.'4 The median
times from onset ofsymptoms to admission and from
admission to first balloon inflation were 122 and 38
minutes, respectively. It is safe, feasible and effective to
identify patients with a large myocardial infarction in
this way in order to transport them directly to a PTCA
centre, thereby preventing the unnecessary visit to a
non-PTCA centre.
Importance of an open vessel at acute
anglography
In a study by Brodie and colleagues, a 13-year follow-
up of 1490 consecutive patients is reported, all of
whom had acute myocardial infarction treated with
aspirin and heparin followed by primary angioplasty.'5
TIMI 2 to 3 flow was present at initial angiography in
18.3% of patients, with TIMI 0 to 1 flow in the re-
mainder. Baseline characteristics were similar between
the two groups, but those patients with an initial open
infarct-related vessel less often presented in cardiogenic
shock (1.7 vs. 9.4%, p<0.0001). Patients with initial
TIMI 2 to 3 flow had lower peak enzyme values
(1328±1529 vs. 2790±2730; p<0.0001), higher acute
(54.3±13.4% vs. 51.6±12.8%; p=0.05) and late
(59.2±14.2% vs. 54.9±13.1%; p=0.004) ejection
fraction and lower 30-day mortality (4.8 vs. 8.9%;
p=0.02). Procedural outcomes (i.e. achievement of
<50% residual narrowing in the infarct-related artery
at the PTCA site with TIMI 2 to 3 flow) were also
better in this group (97.4 vs. 93.8%; p=0.02). Lee et
al. and Stone et al. published comparable results.'16"7
It was found that patients with 'spontaneous' recanal-
isation' (after aspirin and heparin in the emergency
room) ofthe infarct-related vessel had a smaller infarct
size and a better left ventricular function, and Stone
showed that an open (TIMI 3 flow) infarct-related
vessel before intervention was an independent predictor
ofsurvival and clinical outcome compared with patients
without TIMI 2-3 flow at initial angiography. De Luca
et al. recently showed that preprocedural TIMI flow
is an independent predictor of one-year mortality in
high-risk patients (i.e. TIMI risk score .4).18
In conclusion, these data show that if restoration
of antegrade flow occurs before primary angioplasty,
clinical outcomes are better, especially in patients at
high risk of adverse events.
Situation In the Netherlands
In the Netherlands, the chance of being admitted to
a hospital with PTCA facilities is low as only 18 hos-
pitals out of a total of 109 hospitals (17%) have such
facilities. Despite that, an increasing percentage of
patients with acute MI have undergone primary or
rescue angioplasty in recent years [personal communi-
cation]. This is due to an increase in referring patients,
often with large acute myocardial infarctions, to a
centre with PTCA facilities. After PTCA most patients
return to their local hospitals after a short period of
observation and stabilisation. The mean delay due to
transportation and preparation of the cath-lab in
transferred patients in the Zwolle area is reported to
be 60 to 70 minutes. This might be longer in highly
urbanised areas and in hospitals with less experience
with primary angioplasty. Therefore, pharmacological
pretreatment during transportation aimed at restoration
ofTIMI 3 flow before angioplasty and facilitating the
PTCA procedure might be beneficial, even in small
countries like the Netherlands.
Ambulance service structure
In the Netherlands there are 31 ambulance regions
with more than 600 ambulances, all staffed with a
specialised nurse and a driver. After successful ex-
periments with prehospital infarct diagnosis (+ therapy)
in five ambulance regions in the country, all ambulances
are equipped with 12-lead ECG computers using an
algorithm capable ofdiagnosing large acute myocardial
infarction. Combined with the fact that administration
of thrombolytic therapy is part of the continuing
education programme of the ambulance personnel, it
Netherlands Heart Journal, Volume 14, Number 2, February 2006 fCi
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is possible to start the pharmacological pretreatment
(lytic, lIb/AIIa blocker or combination) shortly after
having made the diagnosis in the ambulance.
Facliftated PTCA: which agent?
Aspirin
The beneficial effects of aspirin in patients with acute
myocardial infarction were established in the ISIS-2
(International Study of Infarct Survival).'9 Whether
this beneficial effect may, in part, be due to a higher
initial patency rate has not been studied; however, a
retrospective study showed that patients who received
aspirin and heparin before transportation had a higher
initial patency compared with patients who did not
receive these drugs.20 The prehospital administration
ofaspirin is a simple, inexpensive and widely applicable
treatment option in patients with suspected or con-
firmed acute myocardial infarction.
Heparin
High-dose intravenous bolus heparin (300 U/kg)
together with aspirin (160 mg chewed) before primary
angioplasty showed full coronary reperfusion in a
considerable number ofpatients with acute myocardial
infarction, especially in those who were treated early.2'
TIMI flow grade 3 was seen in 31% ofthe patients and
TIMI flow grade 2 was seen in 20% ofthe patients. It
was suggested that pretreatment with high-dose
heparin might lead to a higher patency rate at initial
angiography. However, in a much larger randomised
trial in which patients with acute myocardial infarction
were randomised to pretreatment with either high-
dose bolus heparin (300 U/kg) or low-dose (0 or
5000 U), this was not confirmed.22 There was no
difference in patency at initial angiography and clinical
endpoints were similar. Within the high-dose heparin
group no benefits were seen with increasing time
between administration of heparin and angiography.
Therefore, based on these data there is no evidence
for pretreatment with high-dose bolus heparin in
patients undergoing primary angioplasty.
Thrombolysis
The PACT (Plasminogen-activator Angioplasty
Compatibility Trial) showed that a 50-mg bolus of
recombinant tissue-type plasminogen activator (rt-PA)
resulted in a significantly higher patency rate compared
with placebo, when it was given as pretreatment at a
mean of 32 minutes ahead of the angiography pro-
cedure.23 However, the primary endpoint ofthe study
(death, re-MI, stroke) was not different and left ven-
tricular function was similar in both treatment groups.
It is still unclear whether pretreatment with thrombo-
lytic agents is beneficial in patients who are being trans-
ported to a PTCA centre. Two small-sized European
Tabe 1. Results of the PRAGUE trial.
Outcome 30 days On-site SK SK+PTCA PTCA P value
Death(%) 14 12 7
Re-MI (%) 10 7 1 p<0.03
Stroke(%) 1 3 0
Death/stroke/re-MI combined (%) 23 15 8 p<0.02
Bleeding (%) 0 8 0
(Re)-PTCA 11 5 4
CABG (%) 3 2 3
No deaths or major complications during transportation.
SK=streptokinase, PTCA=percutaneous transluminal coronary angioplasty, MI=myocardial infarction, CABG=coronary artery bypass graft.
Reprinted with permission from the author.22
Tabe 2. Results of the LIMI trial at 42 days follow-up.
On-ite rt-PA rt-PA+PTCA PTCA P value
(n=75) (n=74) (n=75)
Death (n) 5 6 5 ns
Stroke 2 3 2
Re-MI 7 4 1 ns
Death/stroke/re-MI combined 14 13 8 ns
Minor bleeding (%) 11 21 11
No deaths or major complications during transportation; no severe bleeding complications.
rt-PA=afteplase; PTCA=percutaneous transluminal coronary angioplasty; Ml=myocardial infarction.
Reprinted with permission from the author.23
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studies showed that pretreatment with streptokinase or
t-PA was associated with a worse outcome compared
with transportation without thrombolytic pretreatment
despite the fact that the percentage ofpatients with an
open infarct-related vessel was higher in the pretreated
group (tables 1 and 2).24 25 This was mainly due to a
higher rate ofbleeding and reinfarction in the patients
who were treated with thrombolytic therapy.
Recently the Assessment ofthe Safety and Efficacy of
the New Thrombolytic Regimen (ASSENT 4) study
was stopped prematurely due to a higher incidence of
adverse events in the facilitated PCI arm (table 3).26
Although the 30-day preliminary results showed that
major bleeding and intracranial haemorrhages occurred
more frequently in the combined treatment (i.e.
facilitated PTCA) group, this cannot ftilly explain the
difference in mortality. More detailed information
showed that pretreatment with fall-dose tenecteplase
(TNK) was associated with a higher incidence of
subacute thrombosis and reinfarction, suggesting a
prothrombotic effect of thrombolysis. Recently the
primary endpoint of the study was presented at the
American Heart Association meeting in Dallas and
showed a significantly worse outcome in the patients
pretreated with thrombolysis. Only the patients who
received the full dose of TNK prehospitally in the
ambulance showed a trend towards better outcome,
however, the results of these subanalyses should be
interpreted with caution.
Glycoprotein llb/llla receptor blockers
Abciximab
In 1997 it was shown for the first time that abciximab
has lytic potential when given to patients with acute
MI.27 The GRAPE (Glycoprotein Receptor Antagonist
Patency Evaluation) study was a small-sized pilot trial
which showed that pretreatment with abciximab (250
pg/kg bolus followed by a 12-hour infusion of 10
pg/min) given in the emergency room to patients
awaiting primary angioplasty at a median time of 45
minutes before angioplasty was associated with TIMI
3 flow in about 20% and TIMI 2 or 3 flow in about
40% of the patients at angiography. There was no
difference in percentage ofTIMI 2 or 3 flow between
patients who received abciximab early after onset of
symptoms or later (>2.5 hours).28 The ADMIRAL
(Abciximab before Direct angioplasty and stenting in
Myocardial Infarction Regarding Acute and Long-
term follow-up) study was a randomised, placebo-
controlled study, in which a subanalysis showed that
abciximab, when given early in the ambulance or the
emergency room, was associated with a higher patency
rate, a better left ventricular function and a lower rate
ofdeath and MI compared with placebo.29 However,
patients who received the active agent only shortly
before intervention (in the cath-lab) did not have any
benefit. This is in agreement with the results from the
larger CADILLAC (Controlled Abciximab and Device
Investigation to Lower Late Angioplasty Compli-
cations) and RAPPORT (Reopro in Acute myocardial
infarction and Primary PTCA Organisation Random-
ised Trial) trials which showed no long-term benefit
in patients who received abciximab during or shortly
before the angioplasty procedure.5'30 In conclusion,
abciximab seems useful for facilitation of primary
angioplasty, especially when it is administered early.
Eptifibatide
So far, only very few data are known about the effect
of pretreatment with eptifibatide alone in patients
undergoing angioplasty for acute myocardial infarction.
In a small, nonrandomised study early administration
of eptifibatide before primary angioplasty resulted in
a significantly higher incidence of partial or complete
reperfusion of the infarct-related vessel at baseline
angiography as well as improvement of several
procedural variables, suggesting a decrease in overall
procedure complexity.3
Tirofiban
Several small trials have shown that this agent can be
safely given in patients with acute MI, especially in
combination with low-molecular-weight heparin. The
TIGER-PA (Tirofiban Given in the Emergency Room
Primary Angioplasty) study showed that, when given
in the emergency room, tirofiban (bolus of 10 pg/kg
followed by 0.15 pg/kg/min maintenance) resulted
in a better initial flow ofthe infarct-related vessel with
a lowerTIMI frame count, comparedwith patients who
received the agent 34 minutes later in the cath-lab,
only shordy before angioplasty.32 The recently published
On-TIME trial showed that the administration of
tirofiban, given at a median ofone hour before primary
angioplasty and started either in the ambulance or in
Netherlands Heart Journal, Volume 14, Number 2, February 2006 fi
Table 3. Primary endpoint of ASSENT 4 at 90 days follow-up.
TNK + PCI PCI alone P value
(n= 828) (n=838)
Death/congestive HF, cardiogenic shock 18.8% 13.7% 0.0055
TNK=tenecteplase, PCI=percutaneous coronary intervention, HF=heart failure.
From Van de Werf F, Ross A. American Heart Association Scientific Sessions 2005; Nov 13-16, 2005; Dallas, TX, US.
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the referring hospital, did not significantly improve
TIMI 3 flow of the infarct-related vessel at initial
angiography. Despite an improved patency (i.e. TIMI
2 or TIMI 3 flow), a lower prevalence ofthrombus or
fresh occlusion, and a better myocardial perfusion in
the infarct-related region before primary angioplasty,
no beneficial effect on angiographic or clinical outcome
after primary angioplasty was found, as compared with
initiation oftirofiban in the catheterisation laboratory,
a few minutes before primary angioplasty.33
In a recently published meta-analysis of six ran-
domised trials (three trials with tirofiban and three trials
with abciximab) it was shown that early administration
ofglycoprotein Ilb/Illa receptor blockers in patients
with acute myocardial infarction appeared to improve
patency of the infarct-related vessel before primary
angioplasty with favourable trends for clinical out-
come.34 TIMI flow grade 2 or 3 (41.7 vs. 29.8%) as well
as TIMI flow grade 3 (20.3 vs. 12.2%) were signifi-
cantly more frequent in the early group compared with
the late group: odds ratio 1.69,95% confidence interval
(CI) 1.28 to 2.22 (p<0.001) and odds ratio 1.85, 95%
CI 1.26 to 2.71 (p<0.001), respectively. The early
administration of glycoprotein IIb/IlIa receptor
blockers was associated with a 28% reduction in
mortality from 4.7 to 3.4%, which was not significant
but consistent with similar trends for reinfarction and
the composite ischaemic endpoint.
Combination of (low-dose) thrombolytic therapy and
llb/llla blockade
The SPEED (Strategies for Patency Enhancement in
the Emergency Department) trial was a dose-finding
study investigating the effect ofpretreatment with full-
dose abciximab (bolus 0.25 mg/kg, maintenance
infusion 0.125 mg/kg/min during 12 hours) and
different doses ofreteplase and heparin in patients with
acute MI.35 It was shown that the combination of full-
dose abciximab, low-dose reteplase (two 5U boluses
administered 30 minutes apart) and heparin (60 U/kg,
maximum of 4000 U) resulted in the same patency
rates compared with normal-dose reteplase, and major
bleeding occurred more frequently with reteplase and
abciximab combined compared with reteplase alone
(9.8 vs. 3.7%). However, when the extent of ST-
segment elevation resolution was taken as the endpoint
instead ofpatency, the combination ofabciximab and
low-dose alteplase was associated with faster and better
resolution of ST-segment elevation compared with
pretreatment with thrombolytic therapy alone and a
reduction in angiographically evident thrombus and
residual stenosis.36 The administration ofabciximab
with alteplase did not increase the incidence ofmajor
bleeding compared with alteplase alone.38 In the
ASSENT-3 and GUSTO-V studies, it was shown that
the combination oflow-molecular-weight heparin or
abciximab reduced ischaemic complications but did
not reduce short-term mortality.39'40 In the ASSENT-
3 trial the rate of bleeding episodes and the need for
transfusion were significantly increased with combined
therapy. In the GUSTO-5 trial the rates ofintracranial
haemorrhage and nonfatal strokes were overall the
same for patients treated with half-dose reteplase with
abciximab as for patients treated with standard dose
reteplase. However, combination therapywas associated
with a significant increase in intracranial haemorrhage
among patients over the age of75 (2.1 vs. 1.1%) and
with increases in the risk ofother bleeding events and
the need for transfusion. The risk of intracranial
bleeding was age-dependent.41 In a registry from
Dudek et al. it was also shown that the combination
of (reduced-dose) alteplase and abciximab caused
major bleeding complications in 3% ofpatients.42 The
recently presented BRAVE (Bavarian Reperfusion
Alternatives Evaluation) study showed that no im-
provement in angiographic outcome post primary
angioplasty could be observed, despite a significantly
higher initial patency rate.43 Larger scale studies are
planned to evaluate whether pretreatment with the
combination of lytic and glycoprotein IIb/lIla
blockade, especially with respect to dosage schemes, is
superior to pretreatment with glycoprotein IIb/IIIa
blockade alone in infarct patients undergoing angio-
plasty.4445 These clinical trials should be done to
evaluate the safety of such combination therapies
before they can be applied widely in routine clinical
practice.
Concluslon
With the increasing use of primary angioplasty as
treatment modality for patients with acute MI, also for
patients who primarily present to hospitals without
angioplasty facilities, it is to be expected that more
patients will be transferred to a tertiary centre in the
acute phase ofmyocardial infarction. As an increase in
treatment delay is associated with a worse clinical out-
come, the importance ofan open infarct-related vessel
at acute angiography becomes clear. Pharmacological
pretreatment with the aim to open the infarct-related
vessel during transportation might be beneficial. From
several randomised trials, it becomes evident that a
glycoprotein Ilb/lIla receptor blocker is the agent of
choice for facilitated PTCA when it is administered
early, as initial patency and bleeding complication rates
as well as clinical outcomes seem more favourable
compared with other agents. Glycoprotein IIb/IIIa
receptor blocker therapy should be combined with
administration of250 to 500 mg aspirin intravenously
and low-dose heparin (i.e. 5000 IU) intravenously.
Whether this is safe and (cost-)effective as pretreatment
for patients transported to undergo angioplasty remains
to be evaluated in large clinical trials. U
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